TEM

Over the past six months (March 24, 2026, to September 24, 2026), Tempus AI reported strong Q2 2026 earnings on July 30, 2026, with revenue up 22% year-over-year to $382.5 million, positive net income of $5.6 million, and positive EBITDA of $45 million, driven by 31% growth in oncology testing volume and 36% growth in Data Licensing & Modeling revenue. In July 2026, the company agreed to acquire cancer-testing company Personalis for approximately $1.5 billion, expected to close in late 2026 or early 2027. Strategic collaborations include extending a data license agreement with Recursion on September 21, 2026, launching an initiative to build the largest multimodal whole-genome dataset on September 11, 2026, and securing up to $9.5 million in ARPA-H ADVOCATE funding for autonomous AI in cardiology on September 9, 2026. As of September 24, 2026, TEM stock rose 11.43% in the previous week and 9.38% over the last month, with a 70.88% rise over the past six months, despite a 9.35% decline from September 22, 2025, to September 18, 2026. Analyst outlooks on September 21, 2026, showed an increased expected loss for fiscal year 2026, while the average analyst price target increased by 7.6% to US$68.18 on September 11, 2026.